KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.

Sumanta K Pal, Diederik M Somford, Petros Grivas, Srikala S Sridhar, Shilpa Gupta, Joaquim Bellmunt, Guru Sonpavde, Mark T Fleming, Seth P Lerner, Yohann Loriot, Jean Hoffman-Censits, Begoña P Valderrama, Corina Andresen, Marco J Schnabel, Suzanne Cole, Siamak Daneshmand

Future Oncol 18(21) 2599-2614

PMID35608106
PMCID-
DOI10.2217/fon-2021-1629
发表日期2022-05-24
摘要

摘要

PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract urothelial cancer (85% of patients) or urothelial bladder cancer (15%), susceptible FGFR3 alterations (activating mutations, gene fusions or rearrangements), ≤120 days following radical surgery and ineligible for/or refusing cisplatin-based (neo)adjuvant chemotherapy. Patients receive either oral infigratinib 125 mg or placebo daily on days 1-21 of a 28-day cycle for up to 52 weeks or until recurrence, unacceptable toxicity or death. Primary end point: centrally determined disease-free survival (DFS); secondary end points: investigator-assessed DFS, metastasis-free survival, overall survival and safety/tolerability; exploratory end points: correlative biomarker analysis, quality-of-life and infigratinib pharmacokinetics.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。